CD200R1 and neoplasm: Those reports contrast with a recent study comparing EMT6, LLC1, and B16 cells [15], wherein agonistic anti-CD200R antibodies had no effect on tumour growth, and B16 tumours grew more slowly in CD200-/- mice than in WT mice.